Cell No. : Cell Name
RCB2361 : HS-ES-2R
update : 2023/10/16
|
| Comment | Human cell line derived from epithelioid sarcoma. RCB2360 and RCB2361 were derived from the same patient. HS-ES-1 (RCB2364) was derived from another patient. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Sonobe, Hiroshi
|
| Originator |
Sonobe, Hiroshi
|
| Year of deposit |
2002
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Tissue |
unknown
|
| Disease name |
epithelioid sarcoma, recurrence
|
| Classification |
cancer
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_8715
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
DMEM (low glucose) + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : once/week, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
0
|
| User's Publication |
3
|
| User's Publication |
|
21791
Sasaki M, Kato D, Murakami K, Yoshida H, Takase S, Otsubo T, Ogiwara H.
Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers.
Nat Commun
2024
15(1):4770
PubMed ID: 38839769
DOI: 10.1038/s41467-024-49063-w
|
|
20775
Rasmussen SV, Jin JX, Bickford LR, Woods AD, Sahm F, Crawford KA, Nagamori K, Goto H, Torres KE, Sidoni A, Rudzinski ER, Thway K, Jones RL, Ciulli A, Wright H, Lathara M, Srinivasa G, Kannan K, Huang PH, Grünewald TGP, Berlow NE, Keller C.
Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology.
Clin Transl Med
2022
12(7):e961
PubMed ID: 35839307
DOI: 10.1002/ctm2.961
|
|
13518
Nakayama RT, Pulice JL, Valencia AM, McBride MJ, McKenzie ZM, Gillespie MA, Ku WL, Teng M, Cui K, Williams RT, Cassel SH, Qing H, Widmer CJ, Demetri GD, Irizarry RA, Zhao K, Ranish JA, Kadoch C.
SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters
Nat Genet
2017
49(11):1613-1623
PubMed ID: 28945250
DOI: 10.1038/ng.3958
|
Back
Top
CELL BANK Website
